Trial Profile

An Open-Label Phase 1b Study to Investigate the Preliminary Safety and Activity of Aldoxorubicin Plus Gemcitabine in Subjects With Metastatic Solid Tumors

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 14 Feb 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Aldoxorubicin (Primary) ; Gemcitabine
Indications Solid tumours
Focus Adverse reactions
Sponsors ImmunityBio

Most Recent Events

05 Jun 2017 Status changed from active, no longer recruiting to completed.
16 Aug 2016 Planned End Date changed from 1 Apr 2016 to 1 Dec 2016.
16 Aug 2016 Planned primary completion date changed from 1 Oct 2015 to 1 Dec 2016.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com